E. Nadal , A. Rittmeyer , F. De Marinis , D.H. Lee , S. Gadgeel , N. Vilariño , E. Bria , S. Arulananda , E.H. Cronenberg , V. Antic , E. Bennett , Y. Hu , K. Madden-Raja , P. Williams , H. Prizant , S. Popat
{"title":"7MO:在未经治疗的局部晚期或转移性非小细胞肺癌(NSCLC)患者中,托布单抗(tobe) +铂基化疗(chemo)与派姆单抗(pembrolizumab) +化疗(pembrolizumab)的II期试验","authors":"E. Nadal , A. Rittmeyer , F. De Marinis , D.H. Lee , S. Gadgeel , N. Vilariño , E. Bria , S. Arulananda , E.H. Cronenberg , V. Antic , E. Bennett , Y. Hu , K. Madden-Raja , P. Williams , H. Prizant , S. Popat","doi":"10.1016/S1556-0864(25)00202-3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S11-S12"},"PeriodicalIF":21.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"7MO: A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)\",\"authors\":\"E. Nadal , A. Rittmeyer , F. De Marinis , D.H. Lee , S. Gadgeel , N. Vilariño , E. Bria , S. Arulananda , E.H. Cronenberg , V. Antic , E. Bennett , Y. Hu , K. Madden-Raja , P. Williams , H. Prizant , S. Popat\",\"doi\":\"10.1016/S1556-0864(25)00202-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\"20 3\",\"pages\":\"Pages S11-S12\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1556086425002023\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086425002023","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
7MO: A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.